Sanofi’s Increased Bid For Zentiva Brings Expansion Closer
This article was originally published in The Tan Sheet
Executive Summary
Sanofi-Aventis' expansion plans move closer to fruition with an increased offer for Zentiva, which sells OTC drugs and dietary supplements as well as Rx products in emerging markets in Central and Eastern Europe
You may also be interested in...
Sanofi gets go-ahead for Zentiva buy
The European Commission approves Sanofi-Aventis' acquisition of Czech pharmaceutical firm Zentiva, with Sanofi agreeing to divest products from both companies in certain Central and Eastern European markets to satisfy competition law. Paris-based Sanofi says Feb. 4 it will pay 1,150 Czech Korunas ($52.32 under same-day conversion rates) for each of a minimum of 10.34 million shares of Zentiva stock. With Zentiva, which sells an OTC ibuprofen product called Ibalgin and an herbal nasal decongestant called Pinosol, Sanofi looks to accelerate its growth in emerging European markets (1"The Tan Sheet" Sept. 29, 2008, p. 8)
Merck KGaA Consumer Business Could Flourish In The Right Hands – Analysts
Merck KGaA's weak consumer health business could be an acquisition target for a larger, more geographically diverse and innovative firm, such as Sanofi-Aventis, according to an analysts' report
Sales & Earnings In Brief
GNC profit jumps: General Nutrition Centers says sales increases in each of its three business segments drove a 167 percent increase in its third-quarter net income to $16.3 million. The Pittsburgh-based specialty retailer Nov. 11 says its retail sales grew 3.2 percent to $298.8 million, accounting for 73.2 percent of it total sales of $414.2 million. Sales at GNC franchises were up 2.7 percent to $67.5 million and revenues from manufacturing and wholesale operations increased 19.4 percent to $47.9 million. GNC also reports that during the July-September period it made $7.1 million in non-cash adjustments related to the March 2007 merger of its owners, Ares Management affiliates and the Ontario Teachers' Pension Plan Board (1"The Tan Sheet" Feb. 12, 2007, p. 9). Because Ares and the OTPPB took GNC privately through the merger, the company does not report per-share earnings